“Global antidepressant and anti-anxiety drugs market set to grow to $14bn by 2024,” according to Visiongain

Visiongain has published a new pharma report Global Antidepressant and Anti-anxiety Drugs Market 2019-2029: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs); Atypical Antipsychotics, Tricyclic Antidepressants (TCAs), Serotonin Antagonist and Reuptake Inhibitors (SARIs), Benzodiazepines; Monoamine Oxidase Inhibitors (MAOIs), Major Depressive Disorder (MDD), General Anxiety Disorder (GAD), Panic Disorder (PD), Obsessive Compulsive Disorder (OCD) and others.
The global antidepressant and Anti-anxiety drugs market is estimated to have reached $12.16bn in 2018. In 2018, the SSRIs segment held 26% of the global antidepressant and anti-anxiety drugs market.

The global Antidepressant and Anti-anxiety Drugs Market consists of all drugs with an antidepressant and anti-anxiety action that are used to treat different types of depression and anxiety diseases. The depression and anxiety diseases include Major Depressive Disorder (MDD); Generalized Anxiety Disorder (GAD); Panic Disorder (PD); Obsessive Compulsive Disorder (OCD); and Others. There are many branded antidepressant and anti-anxiety drugs that have been launched in the global markets. The rising prevalence of depression and anxiety diseases and growing healthcare awareness about these diseases is expected to drive the market growth.

Purchase full report or download free sample pages: https://www.visiongain.com/report/global-antidepressant-and-anti-anxiety-drugs-market-2019-2029/

The lead analyst commented that “The growth of the antidepressant and anti-anxiety drugs market has been relatively stagnant due to generic erosion, lack of new antidepressant and anti-anxiety drugs entering the market as well as stringent government regulations. Initiatives to regulate the consumption of antidepressant and anti-anxiety drugs in several national markets, though necessary, have also hampered the growth of this market. The pipeline of antidepressants has shifted to new drug mechanisms, and new drug classes are on the way to growth in this market. The limited market penetration and problems with existing antidepressant therapies mean that drugs with new mechanisms of action, rapid onset of effect and positive safety profiles still have a high commercial potential.”

Leading companies featured in this report include Johnson & Johnson; Eli Lilly and Company; Allergan plc.; AstraZeneca plc.; Pfizer Inc.; GlaxoSmithKline plc.; H. Lundbeck A/S; Pfizer Inc.; Valeant Pharmaceuticals; Otsuka Pharmaceutical Co., Ltd.; and Takeda Pharmaceutical Company Ltd.

Related reports:

Pharma Leader Series: Top Generic Drug Producers Market Forecast 2019-2029:
https://www.visiongain.com/report/pharma-leader-series-top-generic-drug-producers-market-forecast-2019-2029/

Indian Pharmaceutical Market Forecast 2019-2029: https://www.visiongain.com/report/indian-pharmaceutical-market-forecast-2019-2029/

Generic Drugs Market Forecast 2019-2029: https://www.visiongain.com/report/generic-drugs-market-forecast-2019-2029/

For more pharma reports, visit our website: https://www.visiongain.com/industries/pharma/

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on 0207 549 9987

Visiongain Limited
Airport House
Purley Way
Surrey
London
CR0 0XZ
United Kingdom

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

This release was published on openPR.